Australian, U.K. Firms To Join In Creating Early Alzheimer’s Test
This article was originally published in PharmAsia News
Executive Summary
Australia's Alzhyme Pty and Senexis of the United Kingdom have signed an agreement to work on discovering a new way to diagnose Alzheimer's disease. Such a test would be a first for a disease that usually begins years before clinical symptoms are observed. The collaboration is aimed at developing a diagnostic test kit reliable and inexpensive enough to allow routine detection of biomarkers in the blood. The two companies see a $1 billion global market for such a test as the number of cases doubles over the next two decades. (Click here for more